Relay Therapeutics is trading 6.99% down at $18.37, with no clear company-specific catalyst for the October 30 decline identified in available news search. - The company’s scheduled third-quarter results announcement is November 4, not October 30. - The healthcare sector was higher Friday afternoon, while the biotechnology ETF was only modestly lower; available market context does not clearly explain the sharper stock move.